Brief: Insilico Medicine Cayman TopCo Expects FY Loss Attributable Of USD352.1 MLN-USD355.8 MLN
06/03/2026 14:34
March 6 (Reuters) - Insilico Medicine Cayman TopCo 3696.HK: EXPECTS FY LOSS ATTRIBUTABLE OF USD352.1 MILLION-USD355.8 MILLION INSILICO MEDICINE CAYMAN TOPCO SEES REVENUE DECLINE IN RANGE OF USD29.5 MILLION TO USD30.0 MILLION IN FY Further company coverage: 3696.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Insilico Medicine Cayman TopCo
See all newsInSilico Medicine jumps on progress in testing of new weight-loss drug
Development Collaboration
InSilico jumps on collaboration to develop biological frontier foundation models
HK-listed InSilico Medicine climbs as chairman buys shares
Brief: Insilico Medicine Cayman Topco's Chair Purchases Aggregate 113,500 Shares In Sept 4-7